Unknown

Dataset Information

0

Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and ?-conotoxin Vc1.1 via GABAB receptor activation.


ABSTRACT: Neuronal Cav2.1 (P/Q-type), Cav2.2 (N-type), and Cav2.3 (R-type) calcium channels contribute to synaptic transmission and are modulated through G protein-coupled receptor pathways. The analgesic ?-conotoxin Vc1.1 acts through ?-aminobutyric acid type B (GABAB) receptors (GABABRs) to inhibit Cav2.2 channels. We investigated GABABR-mediated modulation by Vc1.1, a cyclized form of Vc1.1 (c-Vc1.1), and the GABABR agonist baclofen of human Cav2.1 or Cav2.3 channels heterologously expressed in human embryonic kidney cells. 50 µM baclofen inhibited Cav2.1 and Cav2.3 channel Ba(2+) currents by ?40%, whereas c-Vc1.1 did not affect Cav2.1 but potently inhibited Cav2.3, with a half-maximal inhibitory concentration of ?300 pM. Depolarizing paired pulses revealed that ?75% of the baclofen inhibition of Cav2.1 was voltage dependent and could be relieved by strong depolarization. In contrast, baclofen or Vc1.1 inhibition of Cav2.3 channels was solely mediated through voltage-independent pathways that could be disrupted by pertussis toxin, guanosine 5'-[?-thio]diphosphate trilithium salt, or the GABABR antagonist CGP55845. Overexpression of the kinase c-Src significantly increased inhibition of Cav2.3 by c-Vc1.1. Conversely, coexpression of a catalytically inactive double mutant form of c-Src or pretreatment with a phosphorylated pp60c-Src peptide abolished the effect of c-Vc1.1. Site-directed mutational analyses of Cav2.3 demonstrated that tyrosines 1761 and 1765 within exon 37 are critical for inhibition of Cav2.3 by c-Vc1.1 and are involved in baclofen inhibition of these channels. Remarkably, point mutations introducing specific c-Src phosphorylation sites into human Cav2.1 channels conferred c-Vc1.1 sensitivity. Our findings show that Vc1.1 inhibition of Cav2.3, which defines Cav2.3 channels as potential targets for analgesic ?-conotoxins, is caused by specific c-Src phosphorylation sites in the C terminus.

SUBMITTER: Berecki G 

PROVIDER: S-EPMC3971658 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and α-conotoxin Vc1.1 via GABAB receptor activation.

Berecki Géza G   McArthur Jeffrey R JR   Cuny Hartmut H   Clark Richard J RJ   Adams David J DJ  

The Journal of general physiology 20140401 4


Neuronal Cav2.1 (P/Q-type), Cav2.2 (N-type), and Cav2.3 (R-type) calcium channels contribute to synaptic transmission and are modulated through G protein-coupled receptor pathways. The analgesic α-conotoxin Vc1.1 acts through γ-aminobutyric acid type B (GABAB) receptors (GABABRs) to inhibit Cav2.2 channels. We investigated GABABR-mediated modulation by Vc1.1, a cyclized form of Vc1.1 (c-Vc1.1), and the GABABR agonist baclofen of human Cav2.1 or Cav2.3 channels heterologously expressed in human e  ...[more]

Similar Datasets

| S-EPMC2014648 | biostudies-other
| S-EPMC9198109 | biostudies-literature
| S-EPMC6633015 | biostudies-literature
| S-EPMC6597251 | biostudies-literature
| S-EPMC5201262 | biostudies-literature
| S-EPMC3644349 | biostudies-literature
| S-EPMC1563181 | biostudies-literature
| S-EPMC3627404 | biostudies-literature
| S-EPMC3931084 | biostudies-literature
| S-EPMC4613612 | biostudies-literature